A Phase 1b/2 Trial of PVSRIPO in Combination With Atezolizumab in Recurrent WHO Grade IV Malignant Glioma
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Atezolizumab (Primary) ; Lerapolturev (Primary)
- Indications Glioma
- Focus Adverse reactions
- 29 Jan 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 21 Oct 2019 Planned End Date changed from 1 Sep 2023 to 1 Jan 2024.
- 21 Oct 2019 Planned primary completion date changed from 1 Sep 2023 to 1 Jan 2024.